SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (420)10/21/2003 11:14:49 AM
From: keokalani'nui  Respond to of 625
 
Not sloppy. ABT may be pointing at competing phage IP, target IP, formulation IP, mnfg IP and, if they marketed it as "Nbrel-Umira", Trademark IP. The more discrete 'IP' ABT points to the more I like CAT's position, SO LONG as the only document at issue is the License Agreement.